|
|
News Breaks | | | | February 11, 2013 | | 08:23 EDT |  | NLNK | NewLink Genetics remains undervalued, says RW Baird
Baird believes NewLink Genetics remains well positioned to outperform its small-cap peers citing near term pivotal data from its leading drug candidate and a strengthened balance sheet. Shares are Outperform rated with a $20 price target. | |
|
News For NLNK From The Last 14 Days Check below for free stories on NLNK the last two weeks. |
|
|
| May 6, 2013 | | 07:49 EDT |  | NLNK | NewLink Genetics reports Q1 EPS (33c), consensus (28c)
 Subscribe for More Information | |
|
|
|
|
|
|
